Scarica l'app Stockscreener
5.21
0.06%
0.0031
Dopo l'orario di chiusura:
5.04
-0.17
-3.26%
Precedente Chiudi:
$5.2069
Aprire:
$5.27
Volume 24 ore:
38,368
Relative Volume:
0.83
Capitalizzazione di mercato:
$13.80M
Reddito:
-
Utile/perdita netta:
$-11.61M
Rapporto P/E:
-0.8215
EPS:
-6.3418
Flusso di cassa netto:
$-9.23M
1 W Prestazione:
+1.17%
1M Prestazione:
-5.10%
6M Prestazione:
-57.06%
1 anno Prestazione:
-62.78%
Intervallo 1D:
$5.04
$5.2761
Intervallo di 1 settimana:
$4.98
$5.35
Portata 52W:
$4.6325
$43.50
Intensity Therapeutics Inc Stock (INTS) Company Profile
Nome
Intensity Therapeutics Inc
Settore
Industria
Telefono
203-221-7381
Indirizzo
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
5.21 | 13.80M | 0 | -11.61M | -9.23M | -6.3418 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Intensity Therapeutics Inc. (INTS) could find a support soon, here's why you should buy the stock now - MSN
Why Intensity (INTS) ability to execute stands out (Slow Grind) 2026-05-05Top Analyst Picks - Newser
Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98 - MSN
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance Singapore
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Intensity Therapeutics (INTS) proxy adds equity plan shares, sets 2026 virtual vote - Stock Titan
Intensity Therapeutics (INTS) price target decreased by 11.32% to 57.29 - MSN
Why Is Retail Going Gaga Over INTS Stocks Today? - MSN
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's what you should know - MSN
Intensity Therapeutics announces pricing of $4M registered direct offering of common stock - MSN
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics (INTS) Institutional Ownership 2026 $INTS - MarketBeat
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - Aktiellt
Why Did INTS Stock Plummet 25% Today? - Dailyhunt
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation - ADVFN
Support Test: Can Intensity Therapeutics Inc disrupt its industryGap Down & Long-Term Safe Investment Ideas - baoquankhu1.vn
Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart
Intratumoral Cancer Therapies Market: Expanding Revenue - openPR.com
Update Report: Is Intensity Therapeutics Inc likely to announce a buybackQuarterly Investment Review & Comprehensive Market Scan Reports - baoquankhu1.vn
Aug Technicals: Does Intensity Therapeutics Inc have a competitive edge2026 Trends & Expert Approved Trade Ideas - baoquankhu1.vn
Aug Fed Impact: Can Intensity Therapeutics Inc benefit from deglobalization2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
RSI Check: What are Intensity Therapeutics Incs recent SEC filings showingPortfolio Update Summary & Weekly Sector Rotation Insights - baoquankhu1.vn
Is Intensity (INTS) Stock Good for Passive Investors | Price at $5.49, Down 2.92%Verified Stock Signals - Newser
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE) - The Globe and Mail
Hedge Fund Bets: What are Intensity Therapeutics Incs recent SEC filings showingMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn
Risk Analysis: What is Intensity Therapeutics Incs debt to equity ratio2026 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Intensity Therapeutics (INTS) CEO receives 37,749-share stock bonus grant - Stock Titan
U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation - The Globe and Mail
Short Squeeze: Is Intensity Therapeutics Inc stock a top performer YTD2026 Momentum & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Intensity Therapeutics, Inc. 2025 Annual Report: Innovative Intratumoral Cancer Drug Development and Clinical Pipeline Overview - Minichart
INTS: Promising clinical results and strong 2025 capital raise extend cash runway into Q2 2027 - TradingView
Clinical data and cash runway update for Intensity Therapeutics (NASDAQ: INTS) - Stock Titan
[10-K] INTENSITY THERAPEUTICS, INC. Files Annual Report - Stock Titan
INTS: Paused clinical trials and ongoing losses highlight urgent need for new funding - TradingView
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Market Pulse: Can Fury Gold Mines Limited expand its profit marginsEarnings Performance Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Intensity Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
US Market Recap: Does Intensity Therapeutics Inc have strong EBITDA margins2026 Sector Moves & Verified Momentum Watchlists - baoquankhu1.vn
Intensity Therapeutics receives new US patent for cancer treatment By Investing.com - Investing.com Australia
Intensity Therapeutics Expands ATM Equity Offering Capacity - The Globe and Mail
Intensity Therapeutics issued new patent in the US - TipRanks
Intensity Therapeutics receives new US patent for cancer treatment - Investing.com
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US - Finviz
Intensity Therapeutics Inc Azioni (INTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):